Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection.
Infections with Pseudomonas aeruginosa have been a long-standing challenge for clinical therapy because of complex pathogenesis and resistance to antibiotics, thus attaching importance to explore effective vaccines for prevention and treatment. In the present study, we constructed a novel DNA vaccine by inserting mutated gene toxAm encoding Pseudomonas Exotoxin A and gene pcrV encoding tip protein of the type III secretion system into respective sites of a eukaryotic plasmid pIRES, named pIRES-toxAm-pcrV, and next evaluated the efficacy of the vaccine in murine acute Pseudomonas pneumonia models. Compared to DNA vaccines encoding single antigen, mice vaccinated with pIRES-toxAm-pcrV elicited higher levels of antigen-specific serum immunoglobulin G (IgG), enhanced splenic cell proliferation and cytokine secretion in response to Pseudomonas aeruginosa antigens, additionally PAO1 challenge in mice airway resulted in reduced bacteria burden and milder pathologic changes in lungs. Besides, it was observed that immunogenicity and protection could be promoted by the CpG ODN 1826 adjuvant. Taken together, it's revealed that recombinant DNA vaccine pIRES-toxAm-pcrV was a potential candidate for immunotherapy of Pseudomonas aeruginosa infection and the CpG ODN 1826 a potent stimulatory adjuvant for DNA vaccination.
Department of Respiratory, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Mingzi
M
Jiang
Department of Respiratory, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Jing
J
Yao
Department of Respiratory, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Ganzhu
G
Feng
D036002:ADP Ribose Transferases / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics* / Q000378:metabolism; D001427:Bacterial Toxins / Q000235:genetics* / Q000378:metabolism; D004195:Disease Models, Animal; D005098:Exotoxins / Q000235:genetics* / Q000378:metabolism; D005260:Female; D008168:Lung / Q000187:drug effects / Q000473:pathology*; D051379:Mice; D009154:Mutation; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology; D052899:Pore Forming Cytotoxic Proteins / Q000235:genetics* / Q000378:metabolism; D011552:Pseudomonas Infections / Q000276:immunology / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*; D054406:Pseudomonas Vaccines / Q000276:immunology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D019444:Vaccines, DNA / Q000276:immunology*; D037521:Virulence Factors / Q000235:genetics* / Q000378:metabolism; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D005098:Exotoxins; D009838:Oligodeoxyribonucleotides; D052899:Pore Forming Cytotoxic Proteins; D054406:Pseudomonas Vaccines; D019444:Vaccines, DNA; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C423449:CpG ODN 1826; C118546:antigen V, Pseudomonas